WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 a.m. PT / 12:00 p.m. ET.
The conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in complement, we ushered in the first new class of complement medicine in 15 years with the approval of the first and only targeted C3 therapy. We are advancing this science to continually develop transformative medicines for people living with rare, retinal, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
CHICAGO, Dec. 16, 2025 /PRNewswire/ -- ABMS AssessLink®, a leading provider of test development and…
CHICAGO, Dec. 16, 2025 /PRNewswire/ -- ABMS AssessLink®, a leading provider of test development and…
WEST DES MOINES, Iowa, Dec. 16, 2025 /PRNewswire/ -- Navigate Wellbeing Solutions announced today the expansion…
WEST DES MOINES, Iowa, Dec. 16, 2025 /PRNewswire/ -- Navigate Wellbeing Solutions announced today the expansion…
Manufacturing Growth Expected in 2026; Revenue to Increase 4.4%; Capital Expenditures to Increase 3%; Capacity…
Manufacturing Growth Expected in 2026; Revenue to Increase 4.4%; Capital Expenditures to Increase 3%; Capacity…